EARLY DIAGNOSIS OF PANCREATIC CANCER
Keywords:
Pancreatic cancer; early diagnosis; MDCT; MRI/MRCP; endoscopic ultrasonography; CA 19-9; PET-CT; resectability.Abstract
Pancreatic cancer (PC) is one of the most aggressive malignant neoplasms of the abdominal organs, characterized by an extremely poor prognosis due to late diagnosis and a high metastatic potential [4], [5]. The five-year survival rate for all stages of the disease does not exceed 11–12%, whereas when detected at stage I it reaches 37–42%, which determines the paramount importance of early diagnosis [1]. The leading instrumental methods for detecting PC are multidetector computed tomography (MDCT) with multiphase contrast enhancement, magnetic resonance imaging with magnetic resonance cholangiopancreatography (MRI/MRCP), and endoscopic ultrasonography (EUS), providing sensitivity of 81–94% and specificity of 82–90% [9], [11]. The serum marker CA 19-9, despite its limited sensitivity in stages I–II (62–82%), remains important in screening high-risk groups [6]. In the present study, a comprehensive analysis of the diagnostic capabilities of the main imaging methods was carried out in 65 patients with histologically verified pancreatic cancer at various stages. It was demonstrated that the use of a multidisciplinary diagnostic algorithm increases the detection rate of resectable tumor forms up to 66.2% [8], [2].
References
Давыдов М.И., Аксель Е.М. Онкология: учебник. — М.: ГЭОТАР-Медиа, 2021. — 768 с.
Патютко Ю.И., Котельников А.Г. Рак поджелудочной железы: диагностика и хирургическое лечение. — М.: Медицина, 2022. — 448 с.
Кубышкин В.А. Хирургия поджелудочной железы. — М.: МЕДпресс-информ, 2020. — 520 с.
Siegel R.L., Miller K.D., Fuchs H.E., Jemal A. Cancer statistics, 2022. — CA: A Cancer Journal for Clinicians. — 2022. — Vol. 72, No. 1. — P. 7–33.
Kleeff J., Korc M., Apte M. et al. Pancreatic cancer. — Nature Reviews Disease Primers. — 2021. — Vol. 7. — P. 1–25.
Canto M.I., Almario J.A., Schulick R.D. et al. Risk of neoplastic progression in individuals at high risk for pancreatic cancer undergoing long-term surveillance. — Gastroenterology. — 2022. — Vol. 162, No. 4. — P. 1152–1163.
Хоронько Ю.В., Кательницкий И.И. Диагностика и лечение рака поджелудочной железы. — Ростов-на-Дону: Феникс, 2022. — 380 с.
Ducreux M., Cuhna A.S., Caramella C. et al. ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of pancreatic cancer. — Annals of Oncology. — 2020. — Vol. 31, No. 8. — P. 1059–1070.
Tamburrino D., Riviere D., Yaghoobi M. et al. Diagnostic accuracy of different imaging modalities for resectability of pancreatic cancer. — Journal of Surgical Oncology. — 2021. — Vol. 124, No. 4. — P. 584–595.
Загайнов В.Е., Орлов С.С. Лучевая диагностика опухолей поджелудочной железы. — Лучевая диагностика и терапия. — 2022. — №3. — С. 12–21.
Yamada Y., Mori H., Matsumoto S. Pancreatic ductal carcinomas: evaluation with multidetector-row CT. — European Radiology. — 2021. — Vol. 31, No. 4. — P. 2541–2554.
Del Chiaro M., Rangelova E., Halimi A. et al. Early detection and prevention of pancreatic cancer: lessons from high-risk cohort studies. — Pancreatology. — 2021. — Vol. 21, No. 6. — P. 1069–1076.
Иванова Е.В., Соколов А.П. Роль эндосонографии в диагностике ранних форм рака поджелудочной железы. — Вопросы онкологии. — 2022. — Т. 68, №4. — С. 445–452.
Pietryga J.A., Morgan D.E. Imaging preoperatively for pancreatic adenocarcinoma. — Journal of Gastrointestinal Oncology. — 2020. — Vol. 11, No. 6. — P. 1138–1154.
Mahajan U.M., Langhoff E., Goni E. et al. Tumour-specific Genetic Biomarkers for the Early Detection of Pancreatic Ductal Adenocarcinoma. — Scientific Reports. — 2022. — Vol. 12. — P. 8669.
Downloads
Published
Issue
Section
How to Cite
